Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc (Nasdaq: RPRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its royalty-based business model, capital structure and portfolio performance. As a company incorporated in England and Wales with Class A ordinary shares listed on The Nasdaq Stock Market LLC under the symbol RPRX, its SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with registration statements and indenture-related documents.
In its filings, Royalty Pharma explains how it acquires and manages royalty interests on biopharmaceutical products and defines key metrics such as Portfolio Receipts, royalty receipts, milestones and other contractual receipts. The company also discloses non-GAAP liquidity measures, including Adjusted EBITDA, ROIC Adjusted EBITDA, Portfolio Cash Flow and ROIE Portfolio Cash Flow, and reconciles these to net cash provided by operating activities. Debt-related filings describe senior unsecured notes issued under an indenture among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as trustee, including coupon rates, maturities, guarantees and covenant terms.
Form 8-K current reports highlight material events such as quarterly earnings releases, debt offerings, changes in directors and other significant corporate developments. These filings can be used to track Royalty Pharma’s capital deployment into new royalty transactions, updates to its share repurchase program, dividend decisions and other actions affecting shareholders.
On Stock Titan’s SEC filings page for RPRX, users can access Royalty Pharma’s latest 10-K, 10-Q and 8-K filings as they are posted to EDGAR. AI-powered summaries help explain complex sections, such as the description of Portfolio Receipts, non-GAAP liquidity measures, and indenture provisions for senior notes, allowing readers to quickly understand the implications of lengthy documents. The page also surfaces Form 4 insider transaction reports, so users can review trading activity by directors and officers alongside the company’s broader disclosure record.
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma plc, filed a Form 4 reporting an exempt acquisition on 08/06/2025 of 21,901 Class A Ordinary Shares at $0 in connection with settlement of Equity Performance Awards pursuant to Rule 16b-3. The transaction is recorded as an exempt award settlement and increases the reporting persons direct holdings.
The filing itemizes extensive indirect beneficial ownership through entities, trusts and family members with specific share counts such as Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 and Legorreta 2023 SR Trust: 600,000, among others.
The form also discloses LP interests in RPI US Partners 2019, LP that are exchangeable under the Amended and Restated Exchange Agreement into Class A Ordinary Shares for no additional value; entries include a reported change dated 08/08/2025 listing 60,000 LP interests (noted as representing 600,000 Class A Ordinary Shares) and larger RPI US LP interest amounts shown for related entities.
Terrance P. Coyne, EVP & CFO of Royalty Pharma plc (RPRX), reported an exempt acquisition on 08/06/2025 of 3,696 Class A Ordinary Shares in connection with the settlement of Equity Performance Awards. The filing shows the award settlement with a $0 price and cites the acquisition as exempt under Rule 16b-3.
The Form 4 shows the reporting person beneficially owned 52,342 Class A Ordinary Shares following the reported transaction, held indirectly through TPC RP EPA1 LLC. The filing also discloses additional indirect holdings including 790,000 shares held by TPC RP 2021, LLC, IRA and spouse accounts, and a reported disposal of 1,500 shares. The form was signed by attorney-in-fact on 08/08/2025.
Royalty Pharma's Form 4 reports that the reporting person listed as "Lloyd George W." (identified as EVP, Investments & CLO) acquired 3,696 Class A Ordinary Shares on 08/06/2025 through the settlement of Equity Performance Awards, an exempt acquisition pursuant to Rule 16b-3. The filing also records a disposition of 3,000 Class A shares and shows multiple indirect holdings held by several related entities and the reporting person's spouse.
Table II discloses limited partnership interests in RPI US Partners 2019, LP that are exchangeable: each RPI US LP Interest may be exchanged for ten Class B Interests, and each Class B Interest will be exchanged for one Class A Ordinary Share, meaning each LP interest converts into ten Class A shares. The filing lists underlying Class A equivalents of 581,730, 2,917,390, 2,726,720, 1,301,480 and 85,000 related to those interests. The form was signed by an attorney-in-fact on 08/08/2025.
Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc (RPRX), reported insider transactions on Form 4. The filing records an exempt acquisition of 3,696 Class A ordinary shares on 08/06/2025 in connection with the settlement of Equity Performance Awards under Rule 16b-3, recorded with a price of $0. The form also shows a reported disposition of 70,000 Class A ordinary shares (marked as a sale).
After the reported activity, the total beneficial ownership is reported as 652,342 shares, held indirectly through SCH Investment Partners LLC. The filing was signed by an attorney-in-fact on behalf of Mr. Hite.
Marshall Urist, EVP, Research & Investments at Royalty Pharma plc (RPRX), reported an exempt acquisition of 2,772 Class A Ordinary Shares in connection with settlement of Equity Performance Awards on 08/06/2025 at $0 per share. Following the reported transaction, the filing shows 39,256 Class A shares beneficially owned directly by the reporting person and additional indirect holdings of 46,667 shares through Sandy Lamm LLC and 19,020 shares through an IRA.
The filing also records acquisition of 3,000 limited partnership interests in RPI US Partners 2019, LP (reported 08/08/2025), which are convertible at the holder's option into 30,000 Class A Ordinary Shares (each LP interest convertible into ten Class B Interests, each Class B exchangeable for one Class A share) for no additional value. Table II indicates 263,412 Class A shares indirectly beneficially owned by Sandy Lamm LLC following the derivative interests reported. The acquisition is characterized as exempt under Rule 16b-3.
Royalty Pharma plc (RPRX) – SEC Form 4 filing discloses that new board member Elizabeth H. Weatherman received two equity grants on 31 Jul 2025.
- Initial grant: 2,752 Class A ordinary share RSUs under the 2020 Independent Director Equity Incentive Plan.
- Pro-rated annual grant: 5,806 Class A ordinary share RSUs under the same plan.
Both RSU tranches carry a $0 purchase price and are scheduled to vest 100 % on the earlier of (i) one-year anniversary of grant or (ii) the first subsequent annual shareholder meeting, subject to plan terms.
Following the grants, Weatherman’s beneficial ownership rises to 8,558 Class A shares, all held directly. No derivative securities were reported.
The filing reflects routine director compensation rather than an open-market purchase; therefore it does not inject fresh cash into the company, nor does it immediately alter share count materially. Nonetheless, the equity-based award modestly aligns the new director’s incentives with shareholders.
Royalty Pharma plc (RPRX) – Form 4 insider transaction:
On 31 Jul 2025, director Carole Ho reported receiving 8,558 Class A ordinary shares through two restricted-stock-unit (RSU) grants issued under the 2020 Independent Director Equity Incentive Plan:
- 2,752 RSUs as an initial equity award.
- 5,806 RSUs as a pro-rated annual award.
Both tranches vest 100 % on the earlier of (i) one year from grant or (ii) the next annual shareholders’ meeting. The awards carry a cost basis of $0, reflect routine board compensation, and increase Ho’s direct ownership to 8,558 shares. No shares were sold, no derivatives were involved, and the filing references no Rule 10b5-1 trading plan. The disclosure is informational and does not affect Royalty Pharma’s fundamentals.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
